---
title: Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
date: '2024-06-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38828951/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240603181443&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Among lenalidomide-exposed patients with relapsed or refractory
  myeloma, BPd conferred a significantly greater benefit than PVd with respect to
  progression-free survival, as well as deeper, more durable responses. Ocular events
  were common but were controllable by belantamab mafodotin dose modification. (Funded
  by GSK; DREAMM-8 ClinicalTrials.gov number, NCT04484623; EudraCT number, ...'
disable_comments: true
---
CONCLUSIONS: Among lenalidomide-exposed patients with relapsed or refractory myeloma, BPd conferred a significantly greater benefit than PVd with respect to progression-free survival, as well as deeper, more durable responses. Ocular events were common but were controllable by belantamab mafodotin dose modification. (Funded by GSK; DREAMM-8 ClinicalTrials.gov number, NCT04484623; EudraCT number, ...